Omalizumab response correlates with reduced IFN‐γ‐, IL‐10‐ and IL‐31‐secreting cells in chronic spontaneous urticaria

Background The anti‐IgE antibody omalizumab has been approved for the treatment of chronic spontaneous urticaria (CSU) in patients insufficiently responding to antihistamines. However, its mode of action in CSU is not clearly understood. Objectives The aim of this study was to get a better insight i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2020-09, Vol.34 (9), p.2078-2085
Main Authors: Rauber, M.M., Pickert, J., Holiangu, L., Möbs, C., Pfützner, W.
Format: Article
Language:English
Subjects:
Anti-Allergic Agents - therapeutic use
Chronic Disease
Chronic Urticaria - drug therapy
Humans
Immunoglobulin E
Interferon-gamma
Interleukin-10
Interleukins
Omalizumab - therapeutic use
T-Lymphocyte Subsets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The anti‐IgE antibody omalizumab has been approved for the treatment of chronic spontaneous urticaria (CSU) in patients insufficiently responding to antihistamines. However, its mode of action in CSU is not clearly understood. Objectives The aim of this study was to get a better insight in the immune mechanisms involved in clinical improvement of CSU patients treated with omalizumab. Methods Chronic spontaneous urticaria patients (n = 15) were followed for 5 months after initiation of omalizumab treatment. Clinical symptoms were assessed by UCT and CU‐Q2oL. Cell‐bound IgE was quantified on both FcεRI‐ and FcεRII‐expressing cell populations in peripheral blood. In addition, IgE and IgG as well as their receptors were measured on basophils, and basophil activation was assessed with different concentrations of anti‐FcεRI and fMLP. Furthermore, the frequencies of different T‐cell subsets secreting IL‐5, IL‐10, IL‐31 or IFN‐γ were analysed by ELISpot assay. Results Seven patients showed a full, five a partial and three no clinical response to omalizumab. Cell‐bound IgE was reduced on FcεRI‐bearing cells, but not on FcεRII‐expressing cells. Likewise, the expression of FcεRI declined. Basophil activation increased upon FcεRI‐stimulation while their sensitivity was not affected. Both basophil and T‐cell frequencies remained unchanged. However, when comparing the individual response to omalizumab treatment with distinct T‐cell subsets, a significant correlation was found between improved UCT and decreased frequencies of IL‐10‐, IL‐31‐ and IFN‐γ‐secreting T cells. Conclusions We here show that besides addressing IgE‐dependent immune mechanisms, omalizumab treatment of CSU patients has effects on distinct T‐cell subsets, which correlate with clinical improvement.
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.16216